Explore our latest news and stories covering technology, retinal health, our people, events, press, and more. You can also follow us on LinkedIn for updates as they happen.
Oxular’s technologies were developed together to find solutions that would solve significant remaining unmet challenges in retinal care. Together, these systems will transform the treatment of retinal disorders.
Oxular is proud to announce it has begun dosing in its OXEYE for diabetic macular edema (DME), a common retinal disorder
As we transition to mid-stage development with our #ophthalmic pipeline and platform, and look to optimize the application of our
Oxular Limited Announces Acceptance of IND for Suprachoroidal OXU-001 for the Treatment of Diabetic Macular Edema OXU-001 represents potential best-in-class
Oxular’s CMO, Friedrich Asmus, MD, spoke at the Dry AMD Therapeutic Development conference in Boston, presenting Oxular’s “Routine Suprachoroidal Drug Administration
Oxular is thrilled to sponsor ISU 2022 in Utrecht, The Netherlands, and introduce the Oxulumis® suprachoroidal microcatheter to leading uveitis
An excellent summary about the potential of our lead program, OXU-001, from Drug Discovery World. “An innovative sustained release
General
+44 (0)1865 636200
inquiries@oxular.com
Magdalen Centre
1 Robert Robinson Avenue
Oxford, OX4 4GA, UK
Limited company registered in
England and Wales
Registration No. 09331313
VAT No. GB 244 5883 81
Copyright Oxular Limited
Media
+1 617 895 9511
monique@thrustsc.com
Monique Allaire
Thrust
Follow us on
Limited company registered in England and Wales (Registration No. 09331313) VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting